Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.
about
Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG islandThe p53-targeting human phosphatase hCdc14A interacts with the Cdk1/cyclin B complex and is differentially expressed in human cancersAlterations in cell cycle and induction of apoptotic cell death in breast cancer cells treated with α-mangostin extracted from mangosteen pericarpLinking sister chromatid cohesion and apoptosis: role of Rad21.A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancerHOXA5-induced apoptosis in breast cancer cells is mediated by caspases 2 and 8COSMIC 2005Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factorsComparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cellsHLA class I and II genotype of the NCI-60 cell linesClinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer GroupMechanisms of drug resistance in colon cancer and its therapeutic strategiesThe fate of chemoresistance in triple negative breast cancer (TNBC)Systems biology of cisplatin resistance: past, present and futureResistance and gain-of-resistance phenotypes in cancers harboring wild-type p53The rebel angel: mutant p53 as the driving oncogene in breast cancer.The role of p53 in cancer drug resistance and targeted chemotherapyAspirin-induced nuclear translocation of NFkappaB and apoptosis in colorectal cancer is independent of p53 status and DNA mismatch repair proficiencyDownregulation of Akt1 inhibits anchorage-independent cell growth and induces apoptosis in cancer cellsFerredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cellsThe bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxelMolecular predictors of survival after adjuvant chemotherapy for colon cancerCisplatinum and taxol induce different patterns of p53 phosphorylationEstrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independenceHigh-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cellsSystematic analyses of the cytotoxic effects of compound 11a, a putative synthetic agonist of photoreceptor-specific nuclear receptor (PNR), in cancer cell linesPTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.ATR-p53 restricts homologous recombination in response to replicative stress but does not limit DNA interstrand crosslink repair in lung cancer cells.Combined xanthorrhizol-curcumin exhibits synergistic growth inhibitory activity via apoptosis induction in human breast cancer cells MDA-MB-231.XIAP is not required for human tumor cell survival in the absence of an exogenous death signalResistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicityAnti-cancer potential of a novel SERM ormeloxifene.Targeting p53 for Novel Anticancer Therapy.Tumor suppressor p53 can participate in transcriptional induction of the GADD45 promoter in the absence of direct DNA bindingDisruption of p53 in human cancer cells alters the responses to therapeutic agentsExpression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous CarcinomasSoft tissue sarcomas and p53 mutationsRelationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cellsPretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs.
P2860
Q21092482-F096E3CA-AE14-4257-AD04-CE1A616C9A7DQ21245741-7CC3750E-CB96-48F1-9EFE-07E72B7EE7D5Q21285004-42C720DD-E433-4A83-B122-B907B4A61913Q24537892-5D53C829-CF55-4B3D-BA97-000FF1986773Q24560000-0EEC0B5C-C51F-40B0-9EC2-52A3F9D0A768Q24603691-0C620CED-310B-4AE8-AD6A-79AA45A0E48AQ24652464-6AAF7696-4FAA-4C65-AB76-115029BD3844Q24685814-72C0CF8C-A5C0-4D4F-9521-CBFD73B5DE19Q24793807-F97C45BE-DCAC-480D-A94A-6003936C219DQ24805062-AC48C93D-68AF-4A6E-BFCF-3F18A814C945Q24806527-50752AB2-8C58-411E-8588-B8638A853029Q26738528-1679C596-33B4-44E1-9C57-A2C9D2DACF48Q26775232-E9F088F0-97B5-4A86-8C49-28AA9673518BQ26863585-41DCD99E-D0D0-4525-87BB-592A8567A252Q27006998-280BD9AB-E0B9-4458-8443-0950D8766170Q27686765-FC48D444-5802-4AA4-89F7-664631D28B8BQ28072553-3425B82D-BA32-4C37-B2C2-B23388F7FE37Q28210586-120EEDFC-1D9E-4822-B7DA-2C5F2A06DF32Q28360348-FB901159-031E-41A0-A709-B985383FA9C2Q28361124-793B3C4A-422A-458D-B2E8-B3FB3414C826Q28362972-274D3C50-8B4D-4525-B26D-FAC3F036FDCDQ28363159-E19F10A0-6824-4605-AF02-55AC6518A264Q28363906-0E74399B-28FA-4445-AF9C-AA7109330D9FQ28396413-EBBC9927-9D4F-404A-B8C2-ED731E8D6155Q28477348-954BB7D4-A065-49AE-A9A5-3E5DEA7E28B9Q28477992-2D8C8873-3BED-4579-BAA6-D54ED274007FQ28533473-B7AD8C61-3593-4D66-A20C-0144D5FAF2ECQ30416701-EE15D816-F21A-4A51-81EE-CAB60C7AF3E7Q31029673-FEEF9FDD-E3F7-40E9-9E32-A550599355B6Q33396839-A15A017F-301F-4F6D-9F28-2FD46C0669A2Q33523404-9A6159A6-1B15-4085-9C91-A05425DE2EC2Q33554192-5B80593B-F5CA-438A-8333-5A3BB91CD746Q33649054-6C9E3281-FB01-45E1-9A96-0A02A7A594F7Q33655329-F6F8A12C-C412-4F53-8C9B-823B947855C9Q33786522-94E3312A-894E-4557-B742-9FD448F23A7DQ33853609-E5C7C4DA-8F54-463C-8B5A-CDF4D23BE3A1Q33865070-A10D4E39-3EE6-477F-8F65-9434DAC19977Q33898768-8FCADBBC-C964-4453-912A-81F1CF50C207Q33927506-D1E9B9F0-FC21-4B72-B8CA-FA91CCFD307AQ33939126-CCF32021-8BA3-4FDD-BDF3-54946A77B142
P2860
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Characterization of the p53 tu ...... ency of 123 anticancer agents.
@en
Characterization of the p53 tu ...... ency of 123 anticancer agents.
@nl
type
label
Characterization of the p53 tu ...... ency of 123 anticancer agents.
@en
Characterization of the p53 tu ...... ency of 123 anticancer agents.
@nl
prefLabel
Characterization of the p53 tu ...... ency of 123 anticancer agents.
@en
Characterization of the p53 tu ...... ency of 123 anticancer agents.
@nl
P2093
P1433
P1476
Characterization of the p53 tu ...... tency of 123 anticancer agents
@en
P2093
D A Scudiero
E A Sausville
J N Weinstein
P M O'Connor
P304
P407
P577
1997-10-01T00:00:00Z